PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1383399
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1383399
Gene Editing Market Forecasts to 2030 - Global Analysis By Product, Technology, Application, End User and By Geography
According to Stratistics MRC, the Global Gene Editing Market is accounted for $7.45 billion in 2023 and is expected to reach $23.05 billion by 2030 growing at a CAGR of 17.5% during the forecast period. A group of technologies known as "gene editing" enables researchers to modify an organism's DNA. These technologies make it possible to change, add, or remove genetic material at particular locations within the genome. Genome editing is a fascinating field for both illness prevention and treatment in humans. More complicated conditions like cancer, heart disease, mental illness, and HIV infection may also be treated and prevented by using it.
According to the National Institutes of Health (NIH), there are approximately 7,000 rare diseases affecting between 25 and 30 million Americans.
Market Dynamics:
Driver:
Rising applications of genomics
Genomics is increasingly being used in food quality and safety testing. Technologies for editing genomes are essential for both finding new drugs and identifying and treating genetic diseases in humans. NGS, DNA analysis and profiling, and genetic engineering of plants and animals all employ genome editing. When evaluating fish populations, NGS can be utilized for DNA barcoding to identify fish eggs and larvae as well as to fully characterize fish communities. Therefore, during the projection period, there will likely be a rise in demand for genome editing technologies due to the expanding application areas of genomics.
Restraint:
High cost
Gene editing therapy research and development can be costly and time-consuming. It could be difficult for businesses and organizations to get the financing needed for in-depth pre- and clinical testing. The development of gene editing medicine heavily relies on clinical studies, which are quite expensive. These trials, which usually involve several phases and a large number of people, are required to show the safety and effectiveness of gene editing therapy. Therefore, high costs are a significant barrier to market expansion.
Opportunity:
Rising prevalence of genetic illnesses
One major factor fueling the gene editing market is the increase in the prevalence of genetic illnesses. An increase in the number of people receiving diagnoses for uncommon diseases and different genetic disorders essentially characterizes this trend. Patients may finally have hope due to gene editing technologies like CRISPR-Cas9, which have the ability to identify and fix the underlying genetic abnormalities causing these illnesses. These factors propel market demand.
Threat:
Off-target impacts of CRISPR
A significant constraint of gene editing technology is the off-target impacts of CRISPR technology. Although CRISPR-Cas9 can target certain genes with astonishing precision, it can also cause unintentional alterations at places other than the intended target. The application of CRISPR technology may present risks and difficulties as a result of this off-target activity. These factors hinder market expansion.
COVID-19 Impact
The industry for gene editing benefited from the pandemic because social distancing norms and a shortage of hospital beds forced home-based patient care systems to adapt to the fullest. The COVID-19 pandemic has changed our lives. It has also intensified the already swift inclinations toward creation and cooperation among the scientific community. With the pandemic spreading across the globe, scientists are working feverishly to develop treatments, vaccinations, and diagnoses. To tackle SARS-CoV-2, the new coronavirus that causes COVID-19, scientists are looking into high-throughput experimental automation, artificial intelligence, and machine learning. The SARS-CoV-2 is necessary for isolating infected patients and observing appropriate medical responses. Thus, the market for gene editing benefited from the COVID-19 epidemic.
The reagents & consumables segment is expected to be the largest during the forecast period
The reagents & consumables segment is estimated to hold the largest share. Reagents and consumables encompass a wide range of items, including foil seals, slide holders, plates, chips, tube strips, library preparation, purification, and target enrichment kits. The market for consumables is predicted to rise as a result of genomics' expanding applicability in a variety of industries. Utilizing NGS in epigenetic and transcriptomics has also been made possible by developments in library preparation technology. Applications for sequencing, including targeted and whole-genome sequencing, employ these kits.
The clustered regularly interspaced short palindromic repeats segment is expected to have the highest CAGR during the forecast period
The clustered regularly interspaced short palindromic repeats segment is anticipated to have lucrative growth during the forecast period. As an alternative to conventional genetic alteration methods, CRISPR-Clustered Regularly Interspaced Short Palindromic Repeats have become an essential tool for gene editing. The Cas9 enzymes set CRISPR apart from previous types of DNA editing. By removing damaged or undesirable DNA sequences, CRISPR reorganizes genes so that the remaining DNA can take on new configurations.
Region with largest share:
North America commanded the largest market share during the extrapolated period. The most significant regional market for gene editing is North America. The US has become this region's main source of revenue. In the US, venture capitalists, governmental organizations, and private companies have made large financial and investment contributions in the gene editing field. Research and development, as well as the commercialization of gene editing technologies, have been accelerated by this financing. The development of therapeutic interventions and the expansion of gene editing businesses have been made possible by the availability of funding.
Region with highest CAGR:
Asia Pacific is expected to witness profitable growth over the projection period. This is due to increasing technological breakthroughs, a thriving biotechnology industry in emerging regions, and the rising prevalence of cancer and other genetic abnormalities. Innovation in CRISPR technology is still growing significantly in Japan. On the other hand, new CRISPR research is anticipated to propel market growth in India. Additionally, researchers in the nation developed a distinct variation of the widely used CRISPR-Cas9 gene-editing method. The variant may increase the accuracy of gene editing without causing unintended DNA changes. Therefore, in the upcoming years, it is anticipated that these variables will have an effect on the Asia-Pacific gene editing market.
Key players in the market
Some of the key players in the Gene Editing Market include: Sangamo Therapeutics, Inc., Beam Therapeutics, Integrated DNA Technologies, Inc., Thermo Fisher Scientific, Horizon Discovery Ltd., Precision Biosciences, CRISPR Therapeutics, GeneScript, Agilent Technologies, Intellia Therapeutics, Inc., Caribou Biosciences, Inc., Lonza, Perkinelmer, Editas, edicine, Tecan Life Sciences, Amsbio and Creative Biogene.
Key Developments:
In November 2022, Thermo Fisher Scientific (US) announced the launch of Gibco CTS AAV-MAX Helper-Free AAV Production System, an all-in-one solution suitable for commercial and clinical applications associated with AAV-based gene therapies.
In June 2022, Lonza (Switzerland) and Adva entered into a license agreement that will allow Adva to develop innovative solutions for the cell and gene therapies industry.
In February 2023, Gen Script (China) announced the expansion of its Singapore facility to provide a premium gene synthesis service. This marks a significant expansion of the company's advanced gene-synthesis capability and enables Gen Script to provide the service levels required for novel vaccine and therapeutic development in life sciences.
Products Covered:
- Software & Systems
- Services
- Reagents & Consumables
Technologies Covered:
- Transcription Activator-Like Effector Nuclease
- Antisense
- Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
- Zinc Finger Nuclease (ZFN)
- Other Technologies
Applications Covered:
- Genetic Engineering
- Cell Line Engineering
- Drug Discovery & Development
- Other Applications
End Users Covered:
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Other End Users
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Technology Analysis
3.8 Application Analysis
3.9 End User Analysis
3.10 Emerging Markets
3.11 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Gene Editing Market, By Product
- 5.1 Introduction
- 5.2 Software & Systems
- 5.3 Services
- 5.4 Reagents & Consumables
6 Global Gene Editing Market, By Technology
- 6.1 Introduction
- 6.2 Transcription Activator-Like Effector Nuclease
- 6.3 Antisense
- 6.4 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
- 6.5 Zinc Finger Nuclease (ZFN)
- 6.6 Other Technologies
7 Global Gene Editing Market, By Application
- 7.1 Introduction
- 7.2 Genetic Engineering
- 7.3 Cell Line Engineering
- 7.4 Drug Discovery & Development
- 7.5 Other Applications
8 Global Gene Editing Market, By End User
- 8.1 Introduction
- 8.2 Academic and Research Institutes
- 8.3 Pharmaceutical and Biotechnology Companies
- 8.4 Other End Users
9 Global Gene Editing Market, By Geography
- 9.1 Introduction
- 9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
- 9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
- 9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa
10 Key Developments
- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies
11 Company Profiling
- 11.1 Sangamo Therapeutics, Inc.
- 11.2 Beam Therapeutics
- 11.3 Integrated DNA Technologies, Inc.
- 11.4 Thermo Fisher Scientific
- 11.5 Horizon Discovery Ltd.
- 11.6 Precision Biosciences
- 11.7 CRISPR Therapeutics
- 11.8 GeneScript
- 11.9 Agilent Technologies
- 11.10 Intellia Therapeutics, Inc.
- 11.11 Caribou Biosciences, Inc.
- 11.12 Lonza
- 11.13 Perkinelmer
- 11.14 Editas Medicine
- 11.15 Tecan Life Sciences
- 11.16 Amsbio
- 11.17 Creative Biogene
List of Tables
- Table 1 Global Gene Editing Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Gene Editing Market Outlook, By Product (2021-2030) ($MN)
- Table 3 Global Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
- Table 4 Global Gene Editing Market Outlook, By Services (2021-2030) ($MN)
- Table 5 Global Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
- Table 6 Global Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
- Table 7 Global Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
- Table 8 Global Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
- Table 9 Global Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
- Table 10 Global Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
- Table 11 Global Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 12 Global Gene Editing Market Outlook, By Application (2021-2030) ($MN)
- Table 13 Global Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
- Table 14 Global Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
- Table 15 Global Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
- Table 16 Global Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 17 Global Gene Editing Market Outlook, By End User (2021-2030) ($MN)
- Table 18 Global Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
- Table 19 Global Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
- Table 20 Global Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 21 North America Gene Editing Market Outlook, By Country (2021-2030) ($MN)
- Table 22 North America Gene Editing Market Outlook, By Product (2021-2030) ($MN)
- Table 23 North America Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
- Table 24 North America Gene Editing Market Outlook, By Services (2021-2030) ($MN)
- Table 25 North America Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
- Table 26 North America Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
- Table 27 North America Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
- Table 28 North America Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
- Table 29 North America Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
- Table 30 North America Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
- Table 31 North America Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 32 North America Gene Editing Market Outlook, By Application (2021-2030) ($MN)
- Table 33 North America Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
- Table 34 North America Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
- Table 35 North America Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
- Table 36 North America Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 37 North America Gene Editing Market Outlook, By End User (2021-2030) ($MN)
- Table 38 North America Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
- Table 39 North America Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
- Table 40 North America Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 41 Europe Gene Editing Market Outlook, By Country (2021-2030) ($MN)
- Table 42 Europe Gene Editing Market Outlook, By Product (2021-2030) ($MN)
- Table 43 Europe Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
- Table 44 Europe Gene Editing Market Outlook, By Services (2021-2030) ($MN)
- Table 45 Europe Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
- Table 46 Europe Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
- Table 47 Europe Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
- Table 48 Europe Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
- Table 49 Europe Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
- Table 50 Europe Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
- Table 51 Europe Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 52 Europe Gene Editing Market Outlook, By Application (2021-2030) ($MN)
- Table 53 Europe Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
- Table 54 Europe Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
- Table 55 Europe Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
- Table 56 Europe Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 57 Europe Gene Editing Market Outlook, By End User (2021-2030) ($MN)
- Table 58 Europe Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
- Table 59 Europe Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
- Table 60 Europe Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 61 Asia Pacific Gene Editing Market Outlook, By Country (2021-2030) ($MN)
- Table 62 Asia Pacific Gene Editing Market Outlook, By Product (2021-2030) ($MN)
- Table 63 Asia Pacific Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
- Table 64 Asia Pacific Gene Editing Market Outlook, By Services (2021-2030) ($MN)
- Table 65 Asia Pacific Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
- Table 66 Asia Pacific Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
- Table 67 Asia Pacific Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
- Table 68 Asia Pacific Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
- Table 69 Asia Pacific Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
- Table 70 Asia Pacific Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
- Table 71 Asia Pacific Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 72 Asia Pacific Gene Editing Market Outlook, By Application (2021-2030) ($MN)
- Table 73 Asia Pacific Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
- Table 74 Asia Pacific Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
- Table 75 Asia Pacific Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
- Table 76 Asia Pacific Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 77 Asia Pacific Gene Editing Market Outlook, By End User (2021-2030) ($MN)
- Table 78 Asia Pacific Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
- Table 79 Asia Pacific Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
- Table 80 Asia Pacific Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 81 South America Gene Editing Market Outlook, By Country (2021-2030) ($MN)
- Table 82 South America Gene Editing Market Outlook, By Product (2021-2030) ($MN)
- Table 83 South America Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
- Table 84 South America Gene Editing Market Outlook, By Services (2021-2030) ($MN)
- Table 85 South America Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
- Table 86 South America Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
- Table 87 South America Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
- Table 88 South America Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
- Table 89 South America Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
- Table 90 South America Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
- Table 91 South America Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 92 South America Gene Editing Market Outlook, By Application (2021-2030) ($MN)
- Table 93 South America Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
- Table 94 South America Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
- Table 95 South America Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
- Table 96 South America Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 97 South America Gene Editing Market Outlook, By End User (2021-2030) ($MN)
- Table 98 South America Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
- Table 99 South America Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
- Table 100 South America Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 101 Middle East & Africa Gene Editing Market Outlook, By Country (2021-2030) ($MN)
- Table 102 Middle East & Africa Gene Editing Market Outlook, By Product (2021-2030) ($MN)
- Table 103 Middle East & Africa Gene Editing Market Outlook, By Software & Systems (2021-2030) ($MN)
- Table 104 Middle East & Africa Gene Editing Market Outlook, By Services (2021-2030) ($MN)
- Table 105 Middle East & Africa Gene Editing Market Outlook, By Reagents & Consumables (2021-2030) ($MN)
- Table 106 Middle East & Africa Gene Editing Market Outlook, By Technology (2021-2030) ($MN)
- Table 107 Middle East & Africa Gene Editing Market Outlook, By Transcription Activator-Like Effector Nuclease (2021-2030) ($MN)
- Table 108 Middle East & Africa Gene Editing Market Outlook, By Antisense (2021-2030) ($MN)
- Table 109 Middle East & Africa Gene Editing Market Outlook, By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) (2021-2030) ($MN)
- Table 110 Middle East & Africa Gene Editing Market Outlook, By Zinc Finger Nuclease (ZFN) (2021-2030) ($MN)
- Table 111 Middle East & Africa Gene Editing Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 112 Middle East & Africa Gene Editing Market Outlook, By Application (2021-2030) ($MN)
- Table 113 Middle East & Africa Gene Editing Market Outlook, By Genetic Engineering (2021-2030) ($MN)
- Table 114 Middle East & Africa Gene Editing Market Outlook, By Cell Line Engineering (2021-2030) ($MN)
- Table 115 Middle East & Africa Gene Editing Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
- Table 116 Middle East & Africa Gene Editing Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 117 Middle East & Africa Gene Editing Market Outlook, By End User (2021-2030) ($MN)
- Table 118 Middle East & Africa Gene Editing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
- Table 119 Middle East & Africa Gene Editing Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
- Table 120 Middle East & Africa Gene Editing Market Outlook, By Other End Users (2021-2030) ($MN)
